Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311738758> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4311738758 abstract "Abstract Background QPX9003 is a fully synthetic lipopeptide with potent activity against MDR Pseudomonas and Acinetobacter spp. This report describes the safety and pharmacokinetics of QPX9003 following single and multiple doses. Methods Twelve healthy subjects were enrolled in 2 cohorts of up to 8 subjects (each cohort randomized to have up to 6 active and 2 placebo) each in the multiple ascending dose phase (100 or 200 mg every 6 hrs). Subjects received a single dose of QPX9003 followed by 48 hours of washout, then were administered QPX9003 q6h for 7 days. All infusions were administered over 1 hour. Intensive plasma sampling was obtained after dosing and assayed for QPX9003 content using validated HPLC/MS methods. Results Single and multiple dose QPX9003 pharmacokinetic parameters (mean +/- SD) are shown below: No subjects discontinued due to AEs and no SAEs were observed. There was no evidence of increasing numbers or severity of AEs with increasing dose, and all AEs were mild or moderate in severity. Conclusion QPX9003 was safe and well tolerated at all doses tested. QPX9003 plasma AUC and Cmax increased with increasing dose. QPX9003 plasma exposure accumulated ∼ 1.5 fold over 7 days of q6h dosing consistent with its plasma half-life. Based on the PK and safety profile, QPX9003 produces plasma exposures that exceed the PK-PD target safely and warrants further clinical development. Disclosures David Griffith, n/a, Qpex Biopharma: Employee Yehuda Carmeli, MD, Allecra Therapeutics: Advisor/Consultant|MSD: Advisor/Consultant|Nabriva: Advisor/Consultant|Pfizer: Advisor/Consultant|Qpex Pharmaceuticals: Advisor/Consultant|Roche: Advisor/Consultant|Shinogi: Advisor/Consultant|Spero Therapeutics: Advisor/Consultant Shawnee Gehrke, n/a, Qpex Biopharma: Employee Elizabeth Morgan, n/a, Qpex Biopharma: Employee Michael Dudley, n/a, ArrePath: Board Member|Qpex Biopharma: Board Member|Qpex Biopharma: Employee Jeff Loutit, MBChB, Qpex Biopharma: Employee." @default.
- W4311738758 created "2022-12-28" @default.
- W4311738758 creator A5019671129 @default.
- W4311738758 creator A5023479710 @default.
- W4311738758 creator A5064877913 @default.
- W4311738758 creator A5077446116 @default.
- W4311738758 creator A5085804402 @default.
- W4311738758 creator A5090474687 @default.
- W4311738758 date "2022-12-01" @default.
- W4311738758 modified "2023-09-30" @default.
- W4311738758 title "217. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects" @default.
- W4311738758 doi "https://doi.org/10.1093/ofid/ofac492.295" @default.
- W4311738758 hasPublicationYear "2022" @default.
- W4311738758 type Work @default.
- W4311738758 citedByCount "3" @default.
- W4311738758 countsByYear W43117387582022 @default.
- W4311738758 countsByYear W43117387582023 @default.
- W4311738758 crossrefType "journal-article" @default.
- W4311738758 hasAuthorship W4311738758A5019671129 @default.
- W4311738758 hasAuthorship W4311738758A5023479710 @default.
- W4311738758 hasAuthorship W4311738758A5064877913 @default.
- W4311738758 hasAuthorship W4311738758A5077446116 @default.
- W4311738758 hasAuthorship W4311738758A5085804402 @default.
- W4311738758 hasAuthorship W4311738758A5090474687 @default.
- W4311738758 hasBestOaLocation W43117387581 @default.
- W4311738758 hasConcept C112705442 @default.
- W4311738758 hasConcept C142724271 @default.
- W4311738758 hasConcept C197934379 @default.
- W4311738758 hasConcept C204787440 @default.
- W4311738758 hasConcept C22979827 @default.
- W4311738758 hasConcept C27081682 @default.
- W4311738758 hasConcept C2777288759 @default.
- W4311738758 hasConcept C2778375690 @default.
- W4311738758 hasConcept C71924100 @default.
- W4311738758 hasConcept C98274493 @default.
- W4311738758 hasConceptScore W4311738758C112705442 @default.
- W4311738758 hasConceptScore W4311738758C142724271 @default.
- W4311738758 hasConceptScore W4311738758C197934379 @default.
- W4311738758 hasConceptScore W4311738758C204787440 @default.
- W4311738758 hasConceptScore W4311738758C22979827 @default.
- W4311738758 hasConceptScore W4311738758C27081682 @default.
- W4311738758 hasConceptScore W4311738758C2777288759 @default.
- W4311738758 hasConceptScore W4311738758C2778375690 @default.
- W4311738758 hasConceptScore W4311738758C71924100 @default.
- W4311738758 hasConceptScore W4311738758C98274493 @default.
- W4311738758 hasIssue "Supplement_2" @default.
- W4311738758 hasLocation W43117387581 @default.
- W4311738758 hasOpenAccess W4311738758 @default.
- W4311738758 hasPrimaryLocation W43117387581 @default.
- W4311738758 hasRelatedWork W2037651778 @default.
- W4311738758 hasRelatedWork W2051764329 @default.
- W4311738758 hasRelatedWork W2064759457 @default.
- W4311738758 hasRelatedWork W2074207917 @default.
- W4311738758 hasRelatedWork W2094883508 @default.
- W4311738758 hasRelatedWork W2319060667 @default.
- W4311738758 hasRelatedWork W3087516196 @default.
- W4311738758 hasRelatedWork W3151787567 @default.
- W4311738758 hasRelatedWork W3178697376 @default.
- W4311738758 hasRelatedWork W4308071420 @default.
- W4311738758 hasVolume "9" @default.
- W4311738758 isParatext "false" @default.
- W4311738758 isRetracted "false" @default.
- W4311738758 workType "article" @default.